M&G Investment Management’s Emergent Biosolutions EBS Stock Holding History

M&G Investment Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,477	Closed	-$5.02K	–	565
2021 Q3	$5.02K	Buy	100,477 +1,113	+1%	+$67.4K	0.01%	409
2021 Q2	$6.26K	Buy	+99,364	New	+$6.38M	0.02%	361
2020 Q4	–	Sell	-4,916	Closed	-$506K	–	460
2020 Q3	$506K	Buy	+4,916	New	+$530K	0.01%	372

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

M&G Investment Management's EBS Position: Q4 2021 in Review

M&G Investment Management sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 100,477 shares — an estimated $5.02K sold.

M&G Investment Management first reported a position in EBS in Q3 2020 and held it in 3 quarters. The position peaked at $506K in Q3 2020. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

M&G Investment Management reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
M&G Investment Management sold 100,477 Emergent Biosolutions shares in Q4 2021, an estimated $5.02K.
M&G Investment Management first reported a position in Emergent Biosolutions in Q3 2020 and held it in 3 quarters.
M&G Investment Management's Emergent Biosolutions position peaked at $506K in Q3 2020.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.